Dr. Robin Downing podcast highlights practical OA pain management
CURRENT BRIEF VERSION: Clinician’s Brief spotlighted a familiar but increasingly complex topic for small-animal practice: how to manage osteoarthritis pain with a practical, multimodal plan. In its sponsored podcast with pain specialist Dr. Robin Downing, the outlet framed OA care as going beyond a single drug choice and toward a broader strategy that combines pain recognition, inflammation control, mobility support, and clearer communication with pet parents. That message also lines up with another recent Clinician’s Brief podcast, in which sports medicine and rehab specialist Dr. Matt Brunke emphasized that mobility and joint health discussions should extend beyond medications and supplements alone, with special attention to often-overlooked cats, obesity, and day-to-day function as a quality-of-life marker. That lands at a moment when canine and feline OA management is evolving quickly, with NSAIDs still central to care, anti-NGF monoclonal antibodies now established in practice, and new safety scrutiny shaping conversations around product selection and monitoring. (cliniciansbrief.com)
Why it matters: For veterinary professionals, the practical takeaway is that OA pain management is becoming more individualized, not simpler. AAHA’s pain guidance supports a tiered, multimodal approach that includes analgesics, weight management, therapeutic exercise, rehabilitation, and environmental modification, while Brunke’s discussion reinforces that mobility plans should account for obesity, conditioning, and functional support in both dogs and cats—not just drug selection. Recent Librela developments have also added both comparative efficacy data versus meloxicam and updated U.S. safety labeling. That means clinics need strong protocols for case selection, follow-up, and pet parent counseling, especially when balancing convenience, comorbidities, adverse-event concerns, and long-term mobility goals. (aaha.org)
What to watch: Expect more discussion around where anti-NGF therapies fit relative to NSAIDs, rehab, weight control, and home-environment changes, as clinicians weigh new trial data, pharmacovigilance signals, and updated labeling in day-to-day OA protocols. (pubmed.ncbi.nlm.nih.gov)